Sirona Biochem Corp. (SRBCF)
USD 0.05
(0.0%)
USD 0.05
(0.0%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 1.61 Million CAD | 3208.18% |
| 2022 | 48.71 Thousand CAD | -32.86% |
| 2021 | 72.55 Thousand CAD | 124.68% |
| 2020 | -293.99 Thousand CAD | 86.55% |
| 2019 | -2.18 Million CAD | -200.69% |
| 2018 | 2.17 Million CAD | -10.12% |
| 2017 | 2.41 Million CAD | 579.48% |
| 2016 | 355.47 Thousand CAD | 343.43% |
| 2015 | -146.02 Thousand CAD | -342.81% |
| 2014 | 60.14 Thousand CAD | 114.64% |
| 2013 | -410.84 Thousand CAD | -1169.14% |
| 2012 | -32.37 Thousand CAD | 75.84% |
| 2011 | -133.99 Thousand CAD | 50.67% |
| 2010 | -271.64 Thousand CAD | -30.08% |
| 2009 | -208.83 Thousand CAD | 12.63% |
| 2008 | -239.03 Thousand CAD | -311.72% |
| 2007 | -58.05 Thousand CAD | 41.94% |
| 2006 | -99.99 Thousand CAD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q3 | 3.28 Million CAD | 21.51% |
| 2024 Q1 | 2.23 Million CAD | 38.67% |
| 2024 Q2 | 2.7 Million CAD | 21.02% |
| 2023 Q1 | 267.84 Thousand CAD | 449.84% |
| 2023 Q3 | 1.35 Million CAD | 101.93% |
| 2023 Q2 | 669.02 Thousand CAD | 149.78% |
| 2023 Q4 | 1.61 Million CAD | 19.28% |
| 2023 FY | 1.61 Million CAD | 3208.18% |
| 2022 Q4 | 48.71 Thousand CAD | 108.32% |
| 2022 Q3 | -585.55 Thousand CAD | 15.97% |
| 2022 Q1 | 625.85 Thousand CAD | 762.57% |
| 2022 Q2 | -696.79 Thousand CAD | -211.34% |
| 2022 FY | 48.71 Thousand CAD | -32.86% |
| 2021 Q4 | 72.55 Thousand CAD | -91.35% |
| 2021 FY | 72.55 Thousand CAD | 124.68% |
| 2021 Q2 | 455.68 Thousand CAD | 81.98% |
| 2021 Q1 | 250.4 Thousand CAD | 185.17% |
| 2021 Q3 | 838.79 Thousand CAD | 84.07% |
| 2020 Q1 | -1.83 Million CAD | 16.0% |
| 2020 FY | -293.99 Thousand CAD | 86.55% |
| 2020 Q3 | -857.81 Thousand CAD | 46.59% |
| 2020 Q2 | -1.6 Million CAD | 12.52% |
| 2020 Q4 | -293.99 Thousand CAD | 65.73% |
| 2019 FY | -2.18 Million CAD | -200.69% |
| 2019 Q4 | -2.18 Million CAD | -67.21% |
| 2019 Q2 | 1.56 Million CAD | -36.05% |
| 2019 Q1 | 2.44 Million CAD | 12.73% |
| 2019 Q3 | -1.3 Million CAD | -183.53% |
| 2018 Q4 | 2.17 Million CAD | -10.41% |
| 2018 FY | 2.17 Million CAD | -10.12% |
| 2018 Q3 | 2.42 Million CAD | -5.75% |
| 2018 Q2 | 2.57 Million CAD | 27.89% |
| 2018 Q1 | 2.01 Million CAD | -16.76% |
| 2017 Q2 | 1.58 Million CAD | 81.8% |
| 2017 Q1 | 870.22 Thousand CAD | 144.81% |
| 2017 Q3 | 2.12 Million CAD | 34.36% |
| 2017 FY | 2.41 Million CAD | 579.48% |
| 2017 Q4 | 2.41 Million CAD | 13.63% |
| 2016 FY | 355.47 Thousand CAD | 343.43% |
| 2016 Q2 | -95.16 Thousand CAD | 46.0% |
| 2016 Q3 | 42.76 Thousand CAD | 144.94% |
| 2016 Q1 | -176.24 Thousand CAD | -20.69% |
| 2016 Q4 | 355.47 Thousand CAD | 731.25% |
| 2015 Q4 | -146.02 Thousand CAD | -128.56% |
| 2015 FY | -146.02 Thousand CAD | -342.81% |
| 2015 Q3 | 511.25 Thousand CAD | 143.0% |
| 2015 Q2 | 210.39 Thousand CAD | -68.67% |
| 2015 Q1 | 671.62 Thousand CAD | 1016.77% |
| 2014 Q3 | 227.54 Thousand CAD | 1406.25% |
| 2014 Q2 | 15.1 Thousand CAD | 113.43% |
| 2014 Q4 | 60.14 Thousand CAD | -73.57% |
| 2014 FY | 60.14 Thousand CAD | 114.64% |
| 2014 Q1 | -112.45 Thousand CAD | 72.63% |
| 2013 Q4 | -410.84 Thousand CAD | -10120.63% |
| 2013 Q3 | 4100.00 CAD | -87.96% |
| 2013 Q2 | 34.04 Thousand CAD | -89.66% |
| 2013 Q1 | 329.19 Thousand CAD | 1116.92% |
| 2013 FY | -410.84 Thousand CAD | -1169.14% |
| 2012 Q2 | -721.11 Thousand CAD | -81.47% |
| 2012 Q4 | -32.37 Thousand CAD | 93.52% |
| 2012 Q3 | -499.18 Thousand CAD | 30.78% |
| 2012 Q1 | -397.37 Thousand CAD | -196.56% |
| 2012 FY | -32.37 Thousand CAD | 75.84% |
| 2011 FY | -133.99 Thousand CAD | 50.67% |
| 2011 Q4 | -133.99 Thousand CAD | 90.59% |
| 2011 Q3 | -1.42 Million CAD | 0.09% |
| 2011 Q1 | -82.75 Thousand CAD | 69.54% |
| 2011 Q2 | -1.42 Million CAD | -1623.06% |
| 2010 Q1 | -229.32 Thousand CAD | -9.81% |
| 2010 FY | -271.64 Thousand CAD | -30.08% |
| 2010 Q4 | -271.64 Thousand CAD | -1161.77% |
| 2010 Q3 | 25.58 Thousand CAD | 145.35% |
| 2010 Q2 | -56.41 Thousand CAD | 75.4% |
| 2009 Q1 | -100.12 Thousand CAD | 58.11% |
| 2009 Q3 | -140.85 Thousand CAD | 0.0% |
| 2009 Q4 | -208.83 Thousand CAD | -48.27% |
| 2009 FY | -208.83 Thousand CAD | 12.63% |
| 2008 Q3 | -58.98 Thousand CAD | -21.99% |
| 2008 FY | -239.03 Thousand CAD | -311.72% |
| 2008 Q2 | -48.34 Thousand CAD | -114.49% |
| 2008 Q1 | -22.54 Thousand CAD | 61.18% |
| 2008 Q4 | -239.03 Thousand CAD | -305.28% |
| 2007 Q1 | -178.48 Thousand CAD | 0.0% |
| 2007 FY | -58.05 Thousand CAD | 41.94% |
| 2007 Q3 | -1.16 Million CAD | -165.92% |
| 2007 Q4 | -58.05 Thousand CAD | 95.03% |
| 2007 Q2 | -439.62 Thousand CAD | -146.31% |
| 2006 FY | -99.99 Thousand CAD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | 15.76 Million USD | 89.777% |
| Nanobac Pharmaceuticals, Incorporated | 4.11 Million USD | 60.868% |
| SQZ Biotechnologies Company | -36.23 Million USD | 104.447% |
| Evofem Biosciences, Inc. | 42.79 Million USD | 96.234% |
| Santhera Pharmaceuticals Holding AG | -6.3 Million USD | 125.561% |
| Mesoblast Limited | 55.85 Million USD | 97.115% |
| Propanc Biopharma, Inc. | 927.18 Thousand USD | -73.803% |
| Genus plc | 190.6 Million USD | 99.155% |
| VioQuest Pharmaceuticals, Inc. | 2.23 Million USD | 27.925% |
| CNBX Pharmaceuticals Inc. | 1.21 Million USD | -32.754% |
| Marizyme, Inc. | 18.56 Million USD | 91.322% |
| ContraFect Corporation | -6.02 Million USD | 126.742% |
| Nymox Pharmaceutical Corporation | 680 Thousand USD | -136.982% |
| PsyBio Therapeutics Corp. | 134.63 Thousand USD | -1096.889% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.15 Million USD | -39.47% |
| Intellipharmaceutics International Inc. | 2.24 Million USD | 28.131% |
| AXIM Biotechnologies, Inc. | 5.5 Million USD | 70.71% |
| MultiCell Technologies, Inc. | 90.04 USD | -1789636.784% |
| Accustem Sciences Inc. | -733.97 Thousand USD | 319.554% |
| RVL Pharmaceuticals plc | 12.94 Million USD | 87.552% |
| EV Biologics, Inc. | 1.36 Million USD | -17.801% |
| Q BioMed Inc. | 4.06 Million USD | 60.308% |
| Emmaus Life Sciences, Inc. | 30.55 Million USD | 94.726% |
| Neon Bloom, Inc. | 622.36 Thousand USD | -158.929% |
| Mosaic ImmunoEngineering Inc. | 1 Million USD | -59.914% |
| Biomind Labs Inc. | 711.4 Thousand USD | -126.522% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Pharming Group N.V. | 109.8 Million USD | 98.532% |
| Oncotelic Therapeutics, Inc. | 12.8 Million USD | 87.417% |
| Skye Bioscience, Inc. | -5.72 Million USD | 128.166% |
| Therapeutic Solutions International, Inc. | 860.24 Thousand USD | -87.329% |
| THC Farmaceuticals, Inc. | 139.8 Thousand USD | -1052.67% |
| Arch Therapeutics, Inc. | 5.64 Million USD | 71.47% |
| IMV Inc. | 7.67 Million USD | 78.991% |
| Acro Biomedical Co., Ltd. | 19.86 Thousand USD | -8011.335% |
| Curative Biotechnology, Inc. | 2.2 Million USD | 26.817% |
| GB Sciences, Inc. | 1.74 Million USD | 7.774% |
| Alpha Cognition Inc. | -183.78 Thousand USD | 976.814% |
| HST Global, Inc. | 96.79 Thousand USD | -1564.871% |
| CSL Limited | 10.52 Billion USD | 99.985% |
| Halberd Corporation | 144.72 Thousand USD | -1013.507% |
| Enzolytics Inc. | 981.65 Thousand USD | -64.159% |
| Resverlogix Corp. | 6.45 Million USD | 75.02% |
| Affymax, Inc. | -5.59 Million USD | 128.792% |
| SYBLEU INC | 473.71 Thousand USD | -240.18% |
| Nuo Therapeutics, Inc. | -673.08 Thousand USD | 339.415% |
| argenx SE | -2.02 Billion USD | 100.079% |
| MetaStat, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | 43.43 Million USD | 96.29% |
| Enzon Pharmaceuticals, Inc. | -47.01 Million USD | 103.428% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| RespireRx Pharmaceuticals Inc. | 2.7 Million USD | 40.505% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | -8.83 Million USD | 118.23% |
| AVAX Technologies, Inc. | -5.9 Million USD | 127.298% |
| Zenith Capital Corp. | 10.06 Thousand USD | -15912.311% |
| Genscript Biotech Corporation | -1.06 Billion USD | 100.152% |
| Ember Therapeutics, Inc. | 200.43 Thousand USD | -704.003% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.38 Million USD | 32.462% |
| WPD Pharmaceuticals Inc. | 164.5 Thousand USD | -879.569% |
| American Oriental Bioengineering, Inc. | 60.54 Million USD | 97.338% |
| Provectus Biopharmaceuticals, Inc. | 1.99 Million USD | 19.402% |
| Adynxx, Inc. | - USD | -Infinity% |
| Helix BioMedix, Inc. | -2.57 Million USD | 162.703% |
| GlobeStar Therapeutics Corporation | 359.71 Thousand USD | -347.994% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 20.27 Million USD | 92.052% |
| Cotinga Pharmaceuticals Inc. | -18.31 Thousand USD | 8897.243% |
| BioStem Technologies, Inc. | 4.47 Million USD | 63.965% |
| ONE Bio Corp. | 9.04 Million USD | 82.174% |
| Reve Technologies, Inc. | 201.25 Thousand USD | -700.719% |
| Burzynski Research Institute, Inc. | -1310.00 USD | 123113.664% |
| Wesana Health Holdings Inc. | 206.21 Thousand USD | -681.448% |
| Agentix Corp. | 37.63 Thousand USD | -4182.318% |
| LadRx Corporation | -2.03 Million USD | 179.131% |
| Cell Source, Inc. | 9.23 Million USD | 82.545% |
| ProtoKinetix, Incorporated | -20.4 Thousand USD | 7996.31% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | -153.709% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | -153.709% |
| NovAccess Global Inc. | 2.17 Million USD | 26.027% |
| Endonovo Therapeutics, Inc. | 7.07 Million USD | 77.21% |
| Itoco Inc. | 228.3 Thousand USD | -605.845% |
| Rasna Therapeutics, Inc. | 135.98 Thousand USD | -1085.007% |
| Pathfinder Cell Therapy, Inc. | 4.95 Million USD | 67.491% |
| Kadimastem Ltd | -253.1 Thousand USD | 736.692% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Institute of Biomedical Research Corp. | 401.84 Thousand USD | -301.016% |
| CytoDyn Inc. | 20.26 Million USD | 92.047% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | -647.00 USD | 249169.397% |
| Mobile Lads Corp. | 484.23 Thousand USD | -232.791% |
| NanoSphere Health Sciences Inc. | -9268.34 USD | 17486.921% |
| Qrons Inc. | 351.42 Thousand USD | -358.553% |
| Alseres Pharmaceuticals, Inc. | 7.7 Million USD | 79.088% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | -249.62 Thousand USD | 745.573% |
| Rebus Holdings, Inc. | 305 Thousand USD | -428.354% |
| ImmunoCellular Therapeutics, Ltd. | 4.45 Million USD | 63.844% |
| International Stem Cell Corporation | 2.59 Million USD | 37.781% |
| Bioxytran, Inc. | 1.89 Million USD | 15.137% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 62.41 Thousand USD | -2481.96% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 2.18 Million USD | 26.109% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 3.43 Million USD | 53.073% |
| Adhera Therapeutics, Inc. | 8.55 Million USD | 81.159% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 772.6 Thousand USD | -108.577% |
| Innovation Pharmaceuticals Inc. | -1.25 Million USD | 228.918% |
| Neutra Corp. | 52.18 Thousand USD | -2987.894% |
| Windtree Therapeutics, Inc. | -2.48 Million USD | 164.744% |
| PureTech Health plc | -167.19 Million USD | 100.964% |
| Coeptis Therapeutics, Inc. | -244.9 Thousand USD | 757.994% |
| IXICO plc | -4.44 Million USD | 136.257% |
| IntelGenx Technologies Corp. | 13.21 Million USD | 87.809% |
| Gelesis Holdings, Inc. | 54.85 Million USD | 97.062% |
| CSL Limited | 10.52 Billion USD | 99.985% |
| Cellectis S.A. | -43.81 Million USD | 103.678% |